Market Overview

UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, Lowers PT

Share:
Related AMRN
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Stocks to Watch for October 23, 2014
Amarin's Vascepa Gains Market Share During The Week Of Presidents' Day (Seeking Alpha)

In a report published Wednesday, Wedbush Securities downgraded its rating on Amarin Corporation (NASDAQ: AMRN) from Outperform to Neutral, and lowered its price target from $22.00 to $15.00.

Wedbush Securities noted, “Downgrading to NEUTRAL from OUTPERFORM on updated risk/reward outlook and lowering fair value to $15 from $22. While we think a buyout of Amarin may still occur, we believe a potential deal price in the $15-20 range is becoming more realistic and is insufficient to outweigh the downside risk of Amarin's launching Vascepa alone, which grows incrementally larger with each passing week. We note that AMRN has risen 464% since July 2010 (vs. a 35% rise in the S&P500 index) and we are stepping to the sidelines to avoid riding shares back to the single-digits in the event that Amarin fails to land a buyer in the near-term.”

Amarin Corporation closed on Tuesday at $12.35.

Latest Ratings for AMRN

DateFirmActionFromTo
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral
May 2014CitigroupDowngradesBuyNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→